● neutral
Impact
PhasePhase 3
Time to marketIf the Phase 3 HARMONY study succeeds, a regulatory filing could follow the topline data (expected 2H 2027), with potential FDA approval potentially 12-18 months later, suggesting a possible 2029-2030 launch at the earliest.
pegtibatinase Updated Nov 2
What to watch
The next major catalyst is the Phase 3 HARMONY topline data readout in 2H 2027. Positive data would position pegtibatinase as the first disease-modifying therapy for classical HCU and likely drive significant upside. Negative data or further manufacturing delays would be substantially damaging, though FILSPARI revenues provide a partial buffer.
Bull case
- Phase 1/2 COMPOSE data showed a 67.1% mean relative reduction in total homocysteine at the highest dose, a strong efficacy signal for a therapy with no currently approved disease-modifying alternative.
- Pegtibatinase has been granted FDA Breakthrough Therapy, Rare Pediatric Disease, Fast Track, and US/EU Orphan Drug designations, which could accelerate regulatory review and provide market exclusivity.
- Multiple sophisticated institutional investors (including Adage Capital, Bank of America, Point72, Marshall Wace, D.E. Shaw, and Wellington Management) added or doubled positions in Q2 2026.
Bear case
- Manufacturing scale-up problems forced a voluntary enrollment pause of the Phase 3 HARMONY study from September 2024 until Q1 2026, raising execution risk and delaying the program by over a year.
- The pivotal Phase 3 topline readout is not expected until the second half of 2027, leaving the stock without a near-term binary catalyst for this program for at least 8-14 months.
- Classical HCU is an ultra-rare disease (estimated <3,000 patients in the US), limiting the commercial ceiling even if approved.